Clinical trial · Interventional
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
Combined Spin- and Gradient-Echo Perfusion Weighted Imaging for Characterizing Vascular Architecture of Brain Lesions
NCT05358340CI-TRIAL-00066272unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objectives of the study are (1) to evaluate the feasibility of using a combined spin- and gradient- echo (SAGE) sequence in dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) and (2) to determine quantitative estimates of vessel density and size to differentiate between areas of radiation necrosis and tumor recurrence.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (DSC MRI)
- interventionNames
- Diagnostic Test: Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI)
Primary outcomes (2)
- measure
- Measurement of perfusion parameter: cerebral blood volume (CBV)
- timeFrame
- Baseline to end of study (up to 2 years)
- description
- Measurements of cerebral blood volume (CBV) will be calculated.
- measure
- Measurement of perfusion parameter: vessel size index (VSI)
- timeFrame
- Baseline to end of study (up to 2 years)
- description
- Measurements of vessel size index (VSI) will be calculated.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with a brain metastasis or primary brain tumour and who will undergo MRI with contrast. Exclusion Criteria: * Subject or subject's legally authorized representative is unable or unwilling to consent to the study. * Subject with documented contrast medium injection contraindication due to severe kidney disease or allergy.
References
Publications (0)
Data not yet available
No reference posted for this study.